ATNX Athenex Inc.

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

As of 12/02/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  06/14/2017
Outstanding shares:  157,410,098
Average volume:  1,048,613
Market cap:   $31,812,581
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF04FC3
Valuation   (See tab for details)
PE ratio:   -0.17
PB ratio:   0.62
PS ratio:   0.29
Return on equity:   -507.59%
Net income %:   -177.11%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy